Diagnosis and Treatment of Latent TB Infection in the Primary Care Setting
Source: Tuberculosis Management in the Primary Care Setting

Video

Now Playing...
In this multimedia module designed for primary care providers, Richard E. Chaisson, MD, reviews best practices in diagnosing and treating patients with latent TB infection. After reviewing this presentation, be sure to consult inPractice HIV and inPractice HIV Africa for comprehensive details on TB epidemiology, diagnosis, and management.

Richard E. Chaisson, MD, has disclosed that he has received consulting fees from Merck and his spouse has an ownership interest in Merck.

Downloads

  • Diagnosis and Treatment of Latent TB Infection in the Primary Care Setting

  • Challenges of Treating Drug-Resistant TB in Developing Countries

    Francesca Conradie MBBCh - 7/9/2014    3 comments / Last Comment: 8/14/2014
    As a clinician treating MDR-TB in South Africa, I am very familiar with the challenges, but new rapid diagnostic tests to detect drug resistance and drugs such as bedaquiline are making a clinical difference.
  • IAS 2015: A Preview of Key Data to Be Presented in Vancouver

    Chris Beyrer MD, MPH - 7/17/2015    6 comments / Last Comment: 8/3/2015
    Here is my take on the most anticipated studies that will be presented in Vancouver this year.
  • Weighing Boosted vs Unboosted Options for a Patient Who Requires Treatment Prior to Availability of Resistance Data

    Eric S. Daar MD - 6/21/2017    
    For a newly-diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART?
  • Recent STI: A Predictor of HIV Acquisition?

    Jeanne Marrazzo MD, MPH - 9/6/2013    2 comments / Last Comment: 12/17/2013
    What approach should you take for a patient you see with a new diagnosis of secondary syphilis who has managed to remain HIV uninfected?
  • Extensively Drug–Resistant Tuberculosis: No Time to Wait

    Richard E. Chaisson MD - 5/12/2014    3 comments / Last Comment: 7/24/2014
    Mortality for patients with XDR-TB is still extremely high. Only newer drugs may make a difference.